Advances in male hormonal contraception

Expert Opinion on Investigational Drugs

Volumn 15, Issue 4, 2006, Pages 389-397

  Meriggiola, Maria Cristina ^a   Pelusi, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Male contraception; Progestins; Spermatogenesis; Testosterone

Indexed keywords

ANDROGEN; CETRORELIX; CYPROTERONE ACETATE; DESOGESTREL; DIENOGEST; ETONOGESTREL; GESTAGEN; GONADORELIN; GONADORELIN ANTAGONIST; GONADOTROPIN; LEVONORGESTREL; MALE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETHISTERONE ENANTATE; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE; TRESTOLONE;

ASIAN; AZOOSPERMIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; HORMONAL CONTRACEPTION; HUMAN; HYPERCHOLESTEROLEMIA; LIVER TOXICITY; MALE; MALE FERTILITY; MEDICAL DECISION MAKING; MONOTHERAPY; NONHUMAN; OLIGOSPERMIA; REVIEW; SPERMATOGENESIS; SPERMATOZOON MATURATION; WEIGHT GAIN;

ANIMALS; ANTISPERMATOGENIC AGENTS; CONTRACEPTION; CONTRACEPTIVE AGENTS, MALE; FEMALE; HORMONE ANTAGONISTS; HUMANS; MALE; PREGNANCY; PREGNANCY RATE;

EID: 33645706434     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.4.389     Document Type: Review

References (63)

1. KAMISCHKE A, NIESCHLAG E: Progress towards hormonal male contraception. Trends Pharmacol. Sci. (2004) 25:49-57.
2. NIESCHLAG E, HENKE A: Hopes for male contraception. Lancet (2005) 365:554-556.
3. WAITES GM: Development of methods of male contraception: impact of the World Health Organization Task Force. Fertil. Steril. (2003) 80:1-15.
4. MARTIN CW, ANDERSON RA, CHENG L et al.: Potential impact of hormonal male contraception: cross-cultural implications for development of novel male preparations. Hum. Reprod. (2000) 15:637-645.
5. HEINEMANN K, SAAD F, WIESEMES M, WHITE S, HEINEMANN L: Attitudes toward male fertility control: results of a multinational survey on four continents. Hum. Reprod. (2005) 20:549-556.
6. HEINEMANN K, SAAD F, WIESEMES M, HEINEMANN L: Expectations toward a novel male fertility control method and potential user types: results of a multinational survey. J. Androl. (2005) 26:155-162.
7. GLASIER AF, ANAKWE R, EVERINGTON D et al.: Would women trust their partners to use a male pill? Hum. Reprod. (2000) 15:646-649.
8. MERIGGIOLA MC, COSTANTINO A, CERPOLINI S: Recent advances in hormonal male contraception. Contraception (2002) 65:269-272.
9. MERIGGIOLA MC, FARLEY TM, MBIZVO MT: A review of androgen-progestin regimens for male contraception. J. Androl. (2003) 24:466-483.
10. ANAWALT BD, AMORY JK: Advances in male hormonal contraception. Ann. Med. (2001) 33:587-595.
11. ANDERSON RA, BAIRD DT: Male contraception. Endocr. Rev. (2002) 23:735-762.
12. WANG C, SWERDLOFF RS: Male contraception. Best Pract. Res. Clin. Obstet. Gynaecol. (2002) 16:193-203.
13. GRIMES D, GALLO M, GRIGORIEVA V, NANDA K, SCHULZ K: Steroid hormones for contraception in men. Cochrane Database Syst. Rev. (2004) 3:CD004316
14. McLACHLAN RI, O'DONNELL L, STANTON PG et al.: Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J. Clin. Endocrinol. Metab. (2002) 87:546-556.
15. LY LP, LIU PY, HANDELSMAN DJ: Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens. Hum. Reprod. (2005) 20:1733-1740.
16. WHO TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY CONTRACEPTIVE: Efficacy of testosterone-induced azoospermia in normal men. Lancet (1990) 336:955-959.
17. WHO TASK FORCE ON METHODS FOR THE REGULATION OF MALE FERTILITY CONTRACEPTIVE: Efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil. Steril. (1996) 65:821-829.
18. TURNER L, CONWAY AJ, JIMENEZ M et al.: Contraceptive efficacy of a depot progestin and androgen combination in men. J. Clin. Endocrinol. Metab. (2003) 88:4659-4667.
19. GU YQ, WANG XH, XU D et al.: A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J. Clin. Endocrinol. Metab. (2003) 88:562-568.
20. NIESCHLAG E, ANDERSON RA, APTER D et al.: Sixth Summit Meeting Consensus: recommendations for regulatory approval for hormonal male contraception. Int. J. Androl. (2002) 25:375.
21. HANDELSMAN DJ, CONWAY AJ, HOWE CJ, TURNER L, MacKEY MA: Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J. Clin. Endocrinol. Metab. (1996) 81:4113-4121.
22. VON ECKARDSTEIN S, NIESCHLAG E: Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a Phase II study. J. Androl. (2002) 23:419-425
23. ZHANG GY, GU YQ, WANG XH, CUI YG, BREMNER WJ: A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J. Androl. (1998) 19:761-768.
24. ZHANG GY, GU YQ, WANG XH, CUI YG, BREMNER WJ: A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J. Clin. Endocrinol. Metab. (1999) 84:3642-3647.
25. KAMISCHKE A, PLOGER D, VENHERM S, VON ECKARDSTEIN S, VON ECKARDSTEIN A, NIESCHLAG E: Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin. Endocrinol. (2000) 53:43-52.
26. CUMMINGS DE, KUMAR N, BARDIN CW, SUNDARAM K, BREMNER WJ: Prostate-sparing effects in primates of the potent androgen 7α-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J. Clin. Endocrinol. Metab. (1998) 83:4212-4219.
27. VON ECKARDSTEIN S, NOE G, BRACHE V et al.: A clinical trial of 7 α-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J. Clin. Endocrinol. Metab. (2003) 88:5232-5239.
28. McLACHLAN RI, ROBERTSON DM, PRUYSERS E et al.: Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J. Clin. Endocrinol. Metab. (2004) 89:142-149.
29. MERIGGIOLA MC, BREMNER WJ, PAULSEN AC et al.: A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J. Clin. Endocrinol. Metab. (1996) 81:3018-3023.
30. MERIGGIOLA MC, BREMNER WJ, COSTANTINO A, DI CINTIO G, FLAMIGNI C: Low dose of cyproterone acetate and testosterone enanthate for contraception in men. Hum. Reprod. (1998) 13:1225-1229.
31. MERIGGIOLA MC, COSTANTINO A, BREMNER WJ, MORSELLI-LABATE AM: Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen. J. Androl. (2002) 23:684-690.
32. MERIGGIOLA MC, COSTANTINO A, CERPOLINI S et al.: Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. J. Clin. Endocrinol. Metab. (2003) 88:5818-5826.
33. ZHANG FP, PAKARAINEN T, POUTANEN M, TOPPARI J, HUHTANIEMI I: The low gonadotropin-independent constitutive production of testicular testosterone is sufficient to maintain spermatogenesis. Proc. Natl. Acad. Sci. USA (2003) 100:13692-13697.
34. WEINBAUER GF, GOCKELER E, NIESCHLAG E: Testosterone prevents the complete suppression of spermatogenesis in the gonadotropin-releasing hormone antagonist-treated non-human primate (Macaca Fascicularis). J. Clin. Endocrinol. Metab. (1988) 67:284-290.
35. SWERDLOFF RS, BAGATELL CJ, WANG C et al.: Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J. Clin. Endocrinol. Metab. (1998) 83:3527-3533.
36. MERIGGIOLA MC, BREMNER WJ, COSTANTINO A et al.: Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. J. Clin. Endocrinol. Metab (2002) 87(5):2107-2113.
37. GU YQ, TONG JS, MA DZ et al.: Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in Chinese men. J. Clin. Endocrinol. Metab. (2004) 89:2254-2262.
38. BEBB RA, ANAWALT BD, CHRISTENSEN RB, PAULSEN CA, BREMNER WJ, MATSUMOTO AM: Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising contraceptive approach. J. Clin. Endocrinol. Metab. (1996) 81:757-762.
39. ANAWALT BD, BEBB RA, BREMNER WJ, MATSUMOTO AM: A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J. Androl. (1999) 20:407-414.
40. ANAWALT BD, AMORY JK, HERBST KL et al.: Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomised clinical trial. J. Androl. (2005) 26:405-413.
41. KAMISCHKE A, PLOGER D, VENHERM S, VON ECKARDSTEIN S, VON ECKARDSTEIN A, NIESCHLAG E: Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin. Endocrinol. (Oxf). (2000) 53(1):43-52.
42. WANG C, WANG HH, NELSON AL et al.: Levonorgestrel implants enhanced the suppression of spermatogenesis by testosterone implants: comparison between Chinese and non-Chinese Men J. Clin. Endocrinol. Metab. (2005) (In Press).
43. GUI YL, HE CH, AMORY JK et al.: Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in Chinese men. J. Androl. (2004) 25:720-727.
44. KAMISCHKE A, VENHERM S, PLOGER D, VON ECKARDSTEIN S, NIESCHLAG E: Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J. Clin. Endocrinol. Metab. (2001) 86:303-309.
45. KAMISCHKE A, HEUERMANN T, KRUGER K et al.: An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J. Clin. Endocrinol. Metab. (2002) 87:530-539.
46. MERIGGIOLA MC, COSTANTINO A, SAAD F et al.: Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis and prostate. J. Clin. Endocrinol. Metab. (2005) 90:2005-2014.
47. WU FC, BALASUBRAMANIAN R, MULDERS TM, COELINGH-BENNINK HJ: Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary - testicular axis, and lipid metabolism. J. Clin. Endocrinol. Metab. (1999) 84:112-122.
48. ANAWALT BD, HERBST KL, MATSUMOTO AM, MULDERS TM, COELINGH-BENNINK HJ, BREMNER WJ: Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high density lipoprotein suppression. Fertil. Steril. (2000) 74:707-714.
49. ANDERSON RA, KINNIBURGH D, BAIRD DT: Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-term acting male contraception. J. Clin. Endocrinol. Metab (2002) 87:3640-3649.
50. BRADY BM, WALTON M, HOLLOW N, KICMAN AT, BAIRD DT, ANDERSON RA: Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. Hum. Reprod. (2004) 19:2658-2667.
51. HAY CJ, BRADY DM, ZITMANN M et al.: A multicenter Phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. J. Clin. Endocrinol. Metab. (2005) 90:2042-2049.
52. BRADY BM, AMORY JK, PERHEENTUPA A et al.: A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Hum. Reprod. (2006) 21:285-294.
53. NIESCHLAG E, HOOGEN H, BOLK M, SCHUSTER H, WICKINGS EJ: Clinical trial with testosterone undecanoate for male fertility control. Contraception (1978) 18:607-614.
54. MERIGGIOLA MC, BREMNER WJ, COSTANTINO A, PAVANI A, CAPELLI M, FLAMIGNI C: An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Ferril. Steril. (1997) 68:844-850.
55. BUCHTER D, VON ECKARDSTEIN S, VON ECKARDSTEIN A et al.: Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J. Clin. Endocrinol. Metab. (1999) 84:1244-1249.
56. GONZALO IT, SWERDLOFF RS, NELSON AL et al.: Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J. Clin. Endocrinol. Metab. (2002) 87:3562-72.
57. HAIR WM, KITTERIDGE K, O'CONNOR DB, WU FC: A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. J. Clin. Endocrinol. Metab. (2001) 86:5201-5209.
58. POLLANEN P, NIKKANEN V, HUHTANIEMI I: Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception. Int. J. Androl. (2001) 24:369-380.
59. PAVLOU SN, BREWER K, FARLEY MG et al.: Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J. Clin. Endocrinol. Metab. (1991) 73:1360-1369.
60. TOM L, BHASIN S, SALAMEH W et al.: Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. J. Clin. Endocrinol. Metab. (1992) 75:476-483.
61. BAGATELL CJ, MATSUMOTO AM, CHRISTENSEN RB, RIVIER JE, BREMNER WJ: Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J. Clin. Endocrinol. Metab. (1993) 77:427-432.
62. NIESCHLAG E, BEHRE HM: Hormonal male contraception: suppression of spermatogenesis with GnRH antagonists and testosterone. In: Treatment with GnRH analogs: controversies and perspectives, Filicori M, Flamigni C (Eds), Parthenon Publishing Group, Italy (1995):243-248.
63. HERBST KL, COVIELLO, AD, PAGE ST, AMORY JK, ANAWALT BD, BREMNER WJ: A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J. Clin. Endocrinol. Metab. (2004) 89:5959-5965.